Source link : https://www.newshealth.biz/health-news/sustained-viral-suppression-in-multidrug-resistant-hiv-with-lenacapavir-at-3-years/
In 3-year data from the CAPELLA study, the subcutaneous, long-acting capsid inhibitor lenacapavir (Sunlenca) demonstrated sustained suppression with no emergence of resistance in highly treatment-experienced individuals with multidrug-resistant HIV. The findings were presented at the recent IDWeek annual meeting in Los Angeles. In this MedPage Today video, Joseph Eron, MD, of the University of North […]
Author : News Health
Publish date : 2024-11-20 17:56:10
Copyright for syndicated content belongs to the linked Source.